Summary for doctors
- First line in advanced HCC; a good option when bevacizumab is unsuitable (varices, bleeding) [1].
- Longer 3-year survival than sorafenib [1].
Dose and schedule
STRIDE
Advanced liver cancer, first line, Child-Pugh ACycle length: Every 4 weeks
Advanced liver cancer, first line, Child-Pugh A
| Drug | Dose | Route | Schedule |
|---|---|---|---|
| First dose | |||
| Tremelimumab | 300 mg | IV | Day 1 (once) |
| Durvalumab | 1500 mg | IV | Day 1, then every 4 weeks |
Evidence: HIMALAYA (2022)
Doses follow the trial protocol, guideline or official drug label (source given in the notes of each regimen). Before prescribing, check blood counts, renal and hepatic function, drug interactions and the patient’s condition, and adjust the dose according to the drug label.
Premedication and supportive care
- Antiviral treatment in active hepatitis B or HBsAg positivity.
- Endoscopy is not required, but treat variceal bleeding.
Monitoring and dose adjustment
- TSH, glucose, liver enzymes and creatinine at baseline and before each cycle; immune-related toxicity as in the immunotherapy toxicity lesson; liver function with the Child-Pugh and ALBI calculator.
Main evidence
Show detailsHide
Related cancer types
Treatment regimens (physicians)
Physician tools and lessons
References
2 referencesShow all references, 1 with a study cardClose the reference list
Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.
- 1
- 2IMJUDO (TREMELIMUMAB) — Prescribing Information
This page is based on reputable scientific sources and was last updated on 28 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.
Printed from the website; the full and up-to-date version: https://drdabiri.com/en/regimens/durvalumab-tremelimumab-hcc/